Angela Märten

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Luis Paz‐Ares, E.H. Tan, Kenneth J. O’Byrne et al. · Annals of Oncology · 2017 · 522 citations · Full text

Medicine, Oncology, Pharmacology +16

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

James Chih‐Hsin Yang, Martin Schüler, Sanjay Popat et al. · Journal of Thoracic Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +14

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Petra Hoffknecht, Amanda Tufman, Thomas Wehler et al. · Journal of Thoracic Oncology · 2014 · 252 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou et al. · Annals of Oncology · 2016 · 188 citations

Pharmacy, Oncology, Pharmacology +17

Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma

Angela Märten, Sabine Renoth, Thomas Heinicke et al. · Human Gene Therapy · 2003 · 148 citations

Medicine, Immunology, Oncology +11